Skip to main content

Table 5 Descriptive data on APOE, CSF, and PET biomarkers, cognitive tests, and statistical outcome (p-values) in one-way (early vs late onset) ANOVA in patients with mild cognitive impairment or sporadic Alzheimer’s disease. Results are given with and without control for the current stage of progression (YECO) on APOE, CSF (Aβ42, total-tau, phosphorylated tau) and PET (neocortical PiB and FDG index) biomarkers, and five cognitive tests (Similarities, Block Design, RAVL learning, RO retention, and Digit Symbol)

From: A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease

Biomarker/test

Early

Late

No control

Control

E vs L

Covariate

E vs L

p

p

p

APOE e4, proportion

1.1 ± 0.8

0.9 ± 0.8

ns

*

**

CSF Aβ42, pgm/mL

584 ± 235

458 ± 177

**

**

ns

CSF total-tau, pgm/mL

476 ± 265

521 ± 241

ns

*

ns

CSF p-tau, pgm/mL

74 ± 27

79 ± 31

ns

ns

ns

PET neocortical PiB

1.42 ± 0.23

1.58 ± 0.24

***

***

ns

PET FDG index

1.52 ± 0.39

1.32 ± 0.29

*

***

ns

Similarities, z-score

 − 0.5 ± 1.2

 − 1.2 ± 1.6

**

***

ns

Block Design, z-score

 − 0.9 ± 0.9

 − 1.7 ± 0.8

***

***

ns

RAVL, z-score

 − 1.2 ± 1.4

 − 2.3 ± 1.3

***

***

ns

RO retention, z-score

 − 0.7 ± 1.1

 − 1.3 ± 0.8

**

***

ns

Digit Symbol, z-score

 − 1.1 ± 1.1

 − 2.2 ± 1.2

***

***

ns

  1. 42, 42 amino variant of beta-amyloid; E, early onset; FDG, fluorodeoxyglucose; L, late onset; PiB, Pittsburgh compound B; p-tau, phosphorylated tau; RAVL, Rey auditory verbal learning; RO, Rey-Osterrieth
  2. * p < 0.05, ** p < 0.01, *** p < 0.001